BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2017 AGM and Awards Gala in Edmonton.
This research unit designs and performs pragmatic trials and research projects that harness the power of real-world health data.
A New Approach to Treating Obstructive Sleep Apnea: Zephyr Sleep Technologies Strikes Strategic Partnership with Dentsply Sirona.
First Patient Enrolled in OncoQuest’s Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer.
Wednesday, July 19, 2017
Quest PharmaTech Inc., an Edmonton-based pharmaceutical company, announce the appointment of Mark Lievonen, to the company's Board of Directors.
Exciton Technologies Receives Approval from China Food and Drug Administration
Licensing agreement will ensure MMDx becomes the standard of care for transplant patients.
New partnerships with the University Hospital Foundation and leading pharmaceutical companies, Servier and Merck, will help dozens of Alberta health innovators market their discoveries to the world.
Edmonton’s General Intermediates of Canada Inc. (GIC) announced they have successfully completed a research project related to a key starting API material for a global pharmaceutical client.
Yesterday the innovative pharmaceutical industry and the Government of Alberta solidified a collaboration to ignite the life sciences sector in Alberta.
Thursday, May 18, 2017
Quest Pharmatech's subsiduary Madenco Biosciences offer new line of "cosmeceuticals" to target needs of dermatologists and medi-spas.
Oncolytic's proprietary immuno-oncology viral agent, REOLYSIN®, gets US FDA fast track approval.
OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer
Major Edmonton biotech firm wins top Innovation Award for 2017 from Country’s top Chinese Business Association.
Friday, March 10, 2017
BioAlberta is surveying the functional food and natural health product industry. Take part!
2016 financials for sales of BioNeutra's low cal, natural sweetener - VitaFiber™ IMO - jumped from $16M in 2015 to $26M in 2016.
Friday, March 17, 2017
On March 16, 2017, Finance Minister Joe Ceci tabled the government's 2017 budget, which included tax credits to benefit the province's high-tech sector.
Wednesday, March 8, 2017
KMT Hepatech Inc. to offer freshly isolated or cryopreserved hyman hepatocytes to pharma, biotech, and other clients
The Canada-Alberta Job Grant (CAJG) is a funding program where employers and government share the cost of training new and existing employees to increase their knowledge and skills to meet the needs of Alberta’s changing economy.
Aquila Diagnostics is pleased to announce that has it been selected to present at the third annual Venture Summit West in Mountain View California on February 28-March 1.
The Alberta Diabetes Institute at the University of Alberta is pleased to announce a collaboration with Janssen Pharmaceuticals and its parent company Johnson & Johnson to advance early-stage technologies related to Type I and Type II diabetes.
Friday, February 10, 2017
Three organizations partner to establish $1.2M Alberta Transplant Innovation Fund. Through collaboration of researchers, clinicians, industry leaders, government and philanthropy, Funding research to improve care of transplant patients.
NanoSpeed Diagnostics announces Test4Ca™ Product Launch at Arab Health Conference in Dubai
Thursday, January 12, 2017
Minister Deron Bilous announces $600,000 fund over next three years in hope that it will bring dividends.